Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen) Europska Unija - hrvatski - EMA (European Medicines Agency)

aripiprazole mylan pharma (previously aripiprazole pharmathen)

mylan pharmaceuticals limited - aripiprazola - schizophrenia; bipolar disorder - psycholeptics - aripiprazol mylan pharma je indiciran za liječenje shizofrenije kod odraslih i adolescenata starijih od 15 godina. Арипипразол Майлана pharma je indiciran za liječenje od umjerenih do teških maničnih epizoda kada je bipolarni poremećaj poremećaj i za prevenciju novog manic epizoda kod odraslih, koji su doživjeli pretežno manične epizode, a čiji je manične epizode odgovorio na арипипразол u liječenju. Арипипразол Майлана pharma je indiciran za liječenje do 12 tjedana umjerenih i teških maničnih epizoda u bipolarni poremećaj kod adolescenata u dobi od 13 godina i stariji.

Cegfila (previously Pegfilgrastim Mundipharma) Europska Unija - hrvatski - EMA (European Medicines Agency)

cegfila (previously pegfilgrastim mundipharma)

mundipharma corporation (ireland) limited - pegfilgrastim - neutropenija - Иммуностимуляторы, - smanjenje duljine trajanja neutropenije i incidencije febrilne neutropenije u odraslih bolesnika liječenih citotoksičnom kemoterapijom zbog zloćudne bolesti (uz iznimku kronične mijeloične leukemije i mijelodisplastičnog sindroma).

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Europska Unija - hrvatski - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogrel hidroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotska sredstva - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Foscan Europska Unija - hrvatski - EMA (European Medicines Agency)

foscan

biolitec pharma ltd - temoporfin - head and neck neoplasms; carcinoma, squamous cell - antineoplastična sredstva - foscan je naznačeno palijativnoj terapiji bolesnika s naprednim glave i vrata planocelularni karcinom neuspjeha prethodne terapije i neprikladan za radioterapiju, operacije ili sustavne kemoterapije.

Nyxoid Europska Unija - hrvatski - EMA (European Medicines Agency)

nyxoid

mundipharma corporation (ireland) limited - naloxone hidroklorid dihidrat - poremećaji povezani s opioidom - svi ostali terapeutski proizvodi - nyxoid je namijenjen za neposrednu primjenu kao hitna terapija ili se sumnja predoziranje opioidima kao depresija dišnog sustava i/ili središnji živčani sustav u postavke ne-medicinskih i zdravstvenih. nyxoid is indicated in adults and adolescents aged 14 years and over. nyxoid is not a substitute for emergency medical care.

Deferasiroks Pharmascience 180 mg filmom obložene tablete Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

deferasiroks pharmascience 180 mg filmom obložene tablete

pharmascience international limited, lampousas, 1, nicosia, cipar - deferasiroks - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži 180 mg deferasiroksa

Deferasiroks Pharmascience 360 mg filmom obložene tablete Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

deferasiroks pharmascience 360 mg filmom obložene tablete

pharmascience international limited, lampousas, 1, nicosia, cipar - deferasiroks - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži 360 mg deferasiroksa

Deferasiroks Pharmascience 90 mg filmom obložene tablete Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

deferasiroks pharmascience 90 mg filmom obložene tablete

pharmascience international limited, lampousas, 1, nicosia, cipar - deferasiroks - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži 90 mg deferasiroksa

Opdualag Europska Unija - hrvatski - EMA (European Medicines Agency)

opdualag

bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanoma - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.

Ledaga Europska Unija - hrvatski - EMA (European Medicines Agency)

ledaga

helsinn birex pharmaceuticals ltd. - chlormethine - mycosis fungoides - antineoplastična sredstva - ledaga je indicirana za topičko liječenje limfoma t-stanica (tipa mf-tipa ctcl) tipa mikoza fungoida u bolesnika odraslih.